secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyell Immunopharma, Inc. (LYEL)
CIK:        0001806952
Form:       8-K
Filed at:   2022-10-06T23:59:59+00:00
Accession:  0001193125-22-258907
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyell Immunopharma receives FDA IND clearance for LYL845 TIL therapy for solid tumors
--------------------------------------------------------------------------------

- FDA cleared IND for LYL845, an autologous TIL therapy enhanced with Epi-R reprogramming technology.
- Phase 1 trial initially enrolling relapsed/refractory metastatic or locally advanced melanoma; expansion into NSCLC and colorectal cancer.
- Initial clinical data expected in 2024; patient screening to begin in coming months.
- LYL845 is Lyell's first TIL product candidate and second wholly owned IND clearance within the past year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806952/000119312522258907/0001193125-22-258907-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806952/000119312522258907/d407382d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-258907

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer